News Search Results
Oct 03, 2025, 06:00 ET Agricultural Biologicals Market worth $34.99 billion by 2030- Exclusive Report by MarketsandMarkets™
While research in biotechnology and microbes has yielded improved efficiencies in products, it has also increased specificity. Biologicals are becoming more attractive to farmers,
More news about: MarketsandMarkets
Oct 02, 2025, 19:30 ET The Inner Circle acknowledges, Michael M. Pennock, MD, MBiot as a Pinnacle Lifetime Member
Bachelor of Science in psychology, with a concentration in neuroscience, from Davidson College in North Carolina. He went on to earn his Master of Biotechnology from Penn State University, and his Doctor of Medicine from Penn State College of Medicine. He completed his residency in radiation oncology, serving
More news about: The Inner Circle
Oct 02, 2025, 15:40 ET Psilera Inc. Secures National Institutes of Health Grant for AUD Research
TAMPA, Fla., Oct. 2, 2025 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biotechnology company developing groundbreaking therapies for hard-to-treat neurological and mental health disorders, today announced receipt of a grant from
More news about: Psilera Inc.
Oct 02, 2025, 14:16 ET Elevate Your Escape: Updates on The Palm Beaches' Newest Hotels, Dining, Events & Attractions
redefining hair vitality. Miriam Quevedo's opulent, high-performance formulas are rooted in a revolutionary "scalp-first" approach, merging advanced biotechnology with rare, precious ingredients such as 24K bioactive gold, rose stem cells, platinum and diamonds, and caviar extract.
More news about: Discover The Palm Beaches
Oct 02, 2025, 12:00 ET Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in Obesity
NORTHBROOK, Ill., Oct. 2, 2025 /PRNewswire/ -- Endevica Bio, a clinical-stage biotechnology company pioneering peptide therapeutics for metabolic diseases, announced a major scientific breakthrough that could redefine the therapeutic landscape
More news about: Endevica Bio
Oct 02, 2025, 11:36 ET ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease
Addressing Critical Unmet Medical Need ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine platform targeting Alzheimer's disease. Current Alzheimer's
More news about: ExQor Technologies Inc
Oct 02, 2025, 09:00 ET LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Oct 02, 2025, 08:30 ET Why Caregiver Experience Belongs in Evidence Generation, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 02, 2025, 08:30 ET Safety for Biosimilars: Strategic Pharmacovigilance Solutions, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 02, 2025, 08:30 ET Preclinical Drug Discovery: Turning Drug Safety Data into Decisions, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Oct 02, 2025, 08:05 ET INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Oct 02, 2025, 08:00 ET CELLS and FITCI Partner to Launch a Community Biotechnology Lab
announced the establishment of the CELLS BioMakerSpace at FITCI. This new community biotechnology lab is designed to foster "bioliteracy" and provide a safe, accessible space for the public to learn about and explore biotechnology.
More news about: Frederick Innovative Technology Center, Inc.
Oct 02, 2025, 08:00 ET Aminex Therapeutics Announces FDA Orphan Drug Designation Granted to AMXT 1501 in Combination with DFMO for the Treatment of Neuroblastoma
Aminex Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for rare and difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration
More news about: Aminex Therapeutics, Inc.
Oct 02, 2025, 08:00 ET Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2025 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced the U.S. Food and Drug
More news about: Calico
Oct 02, 2025, 08:00 ET ADVANCION EXPANDS U.S. MANUFACTURING CAPABILITIES WITH LAUNCH OF COMMERCIAL MOPS BUFFER PRODUCTION
ABOUT ADVANCIONAdvancion is a leading global producer of specialty ingredients and consumables for biotechnology, pharmaceuticals, home, personal care, and other consumer-oriented and industrial markets. The Company is one of the world's largest producers of
More news about: Advancion Corporation
Oct 02, 2025, 07:50 ET AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing
AI Drug Discovery Platform powered by Nvidia, HP, and Equinix NYB is an AI-driven drug discovery and biotechnology company. Its flagship Vecura™ AI platform, powered by the proprietary DTIGN, translates vast biochemical spaces into feasible drug candidates. In
More news about: NYB Holdings Limited
Oct 02, 2025, 07:00 ET OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates
ROCKVILLE, Md., Oct. 2, 2025 /PRNewswire/ -- OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund, and supported by
More news about: OncoC4
Oct 02, 2025, 07:00 ET The9's Singapore Investee NYB Announce Plan to Go Nasdaq via US$1.5 Billion Business Combination with SPAC RF Acquisition Corp II
About NYB Nanyang Biologics (NYB) is an AI-driven drug discovery and biotechnology company accelerating the future of medicine through the convergence of artificial intelligence and natural compounds. Its flagship Vecura™ AI platform,
More news about: The9 Limited
Oct 02, 2025, 06:36 ET ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease
Addressing Critical Unmet Medical Need ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine platform targeting Alzheimer's disease. Current Alzheimer's
More news about: ExQor Technologies Inc
Oct 01, 2025, 13:37 ET Wheeler Bio Appoints Jay Benson as Chief Operating Officer
resilient biomanufacturing operations enables Wheeler to deliver on its mission of providing agile, domestic biologics manufacturing capacity for biotechnology innovators. As the demand for U.S. based biomanufacturing increases, Wheeler Bio's ModularCMC™ platform is well positioned to streamline the path
More news about: Wheeler Bio, Inc.
Oct 01, 2025, 12:49 ET Five Rubin Rudman Attorneys Named to 2026 Lawdragon 500 Leading Corporate Employment Lawyers
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Oct 01, 2025, 09:48 ET French Riviera Hosts Powerful 27th Global Family Office Investment Summit Hosted by Anthony Ritossa
Real Estate, Private Equity & Global Markets Cross-border Co-Investments Healthcare, Biotechnology & Longevity Philanthropy, Family Governance & Legacy Planning
More news about: Ritossa Family Office
Oct 01, 2025, 09:30 ET Epilepsy Foundation of America Welcomes Four New Members to National Board of Directors
Michigan. Kathleen W. Tregoning is a purpose-driven leader with more than 20 years of experience in the biotechnology industry, spanning start-ups to global enterprises. She has guided organizations through growth, transformation, and change while holding senior
More news about: Epilepsy Foundation
Oct 01, 2025, 09:21 ET Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
Oct. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced its participation in a fully funded Australian Medical Research Future
More news about: Kazia Therapeutics Limited